THE APEX TIMES
Jim Cramer tells viewers to hold Moderna after a phase 3 cancer-trial milestone
In a recent Mad Money segment, Cramer focused on Moderna’s mRNA platform as a caller recounted a sharp move in the stock and asked whether to sell or hold after a phase 3 cancer trial update.
On the Aug. 26 episode of Mad Money, Jim Cramer discussed Moderna (NASDAQ: MRNA) after a caller described buying 1,000 shares at about $54 a few weeks earlier, watching the shares rise sharply to around $150, and asking what to do next.
The caller’s question centered on Moderna’s involvement in a phase 3 cancer trial. Cramer’s response, as described in the segment recap, was straightforward: “hold” Moderna despite the large run-up.
Cramer’s broader framing was that Moderna’s research pipeline, particularly where it reaches late-stage clinical testing, matters for shareholders who are deciding whether recent price momentum reflects durable scientific progress or just short-term trading.
While the recap highlights the phase 3 cancer trial theme, it does not provide additional specifics on the trial’s indication, endpoints, or the magnitude of any reported clinical results. It also does not spell out whether the latest share-price jump was tied to a particular press release, an earnings event, or broader market reaction.
The segment also played out in the context of what mRNA companies typically face when moving from earlier studies into phase 3. Phase 3 trials are intended to validate effectiveness and safety at scale, and investors often treat positive or even ambiguous late-stage data as a potential inflection point for both revenue expectations and partner interest.
Moderna, which is listed on Nasdaq, is part of the wider healthcare sector’s push toward mRNA-based therapies and vaccines. mRNA platforms work by delivering instructions to cells that can help produce disease-relevant targets, a model that has historically driven the company’s commercial strategy and capital-market attention.
That said, the Yahoo Finance recap does not include the trial data details that would normally allow readers to independently assess whether the news justifies a hold recommendation, or whether additional confirmatory information is expected before investors can fully price the opportunity.
What to watch next will likely be whether Moderna provides fuller phase 3 readouts or follow-on updates tied to the cancer program discussed on air, and whether management’s disclosures clarify the commercial timeline for any eventual therapy or partnership. Until then, the segment provides a market view on sentiment rather than a substitute for trial-level evidence.
Why It Matters
- Late-stage clinical updates often drive sharp repricing in biotech stocks, and the segment reflects that dynamic.
- The recommendation underscores how investors can anchor on phase 3 progress when deciding how to respond to volatility.
- Because the recap does not detail trial metrics, it highlights the gap between market narratives and the underlying clinical evidence investors will eventually need.
- For healthcare investors, the timing and completeness of Moderna’s disclosures remain central to how sustainable any post-update price moves may be.
Key Facts
- A Mad Money segment aired Aug. 26 featured discussion of Moderna (MRNA) after a phase 3 cancer-trial reference.
- A caller said they bought 1,000 shares of Moderna around $54 and later saw the stock rise to about $150.
- The caller asked whether to sell or hold after the stock’s rise.
- Cramer’s advice in the recap was to hold Moderna.
- The recap emphasizes the phase 3 cancer trial theme but does not lay out trial endpoints or detailed results.
Healthcare Related
OmniAb’s ion-channel deal with Eli Lilly puts a small biotech’s platform in front of a major drugmaker
OmniAb, Inc. said it has entered a global collaboration and licensing agreement with Eli Lilly to discover and develop new ion channel therapeutics, a strategy that could validate OmniAb’s technology even as key financial and scientific details remain undisclosed.
GLP-1 coverage slips from 72% to 60%, but Eli Lilly posts a surge as weight-loss drugs keep selling
A drop in employer insurance coverage for GLP-1 weight-loss drugs is emerging as a new constraint, even as Eli Lilly reports a steep jump in revenue linked to its obesity medicines.
Pfizer and BioNTech say FDA approved a supplemental COVID-19 vaccine adapted for XFG variant
The companies announced U.S. regulatory approval for an additional version of their jointly developed mRNA COVID-19 vaccine, underscoring the continuing cycle of variant updates.
AM Best affirms UnitedHealth’s credit ratings at “a-,” maintaining long- and short-term issue ratings
The rating agency said it reaffirmed UnitedHealth Group’s long-term issuer credit rating and related long- and short-term issue credit ratings for the company and its subsidiaries.
Moderna Q2 earnings spotlighted as analysts place its results in the wider therapeutics-stock landscape
A Yahoo Finance wrap-up of second-quarter results put Moderna’s performance in context with other healthcare therapeutics stocks, underscoring how investors weigh growth, pipeline progress, and near-term fundamentals.
FDA approval expands Eli Lilly’s Mounjaro to help reduce heart attack and stroke risk in high-risk Type 2 diabetes patients
The agency has cleared Mounjaro for a new indication aimed at lowering the risk of major cardiovascular events among adults with Type 2 diabetes who are considered at higher risk for heart attack or stroke.
Jim Cramer cited Johnson & Johnson’s balance sheet as a reason investors should look past worries
A recent Yahoo Finance report highlighted CNBC host Jim Cramer’s recurring bullish view of Johnson & Johnson, pointing to what he framed as a stronger balance sheet than the government’s.
Novo’s Wegovy pill draws China acceptance, but Lilly’s lead in the queue remains central
A regulatory step in China for Novo’s obesity medicine supports the possibility of a future launch, yet it does not resolve timing risks or guarantee approval. Eli Lilly still has a prominent position as the battle over GLP-1 oral therapy extends.
Pfizer begins shipments of its updated COVID-19 vaccine aimed at older and high-risk patients
The company’s newly updated shot, adapted from its XFG program, is being rolled out with deliveries starting immediately to pharmacies and clinics.
Lilly’s Mounjaro franchise grows after FDA expands label into heart-risk population
Eli Lilly (LLY) says the FDA decision broadens Mounjaro’s U.S. use beyond glucose control, adding a heart-risk label that strengthens its competitive position in cardiometabolic care.